Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32857647.
- Also identified by DOI 10.18553/jmcp.2020.26.9.1077 and PMC identifier 10391108.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
No funding was received for this commentary. The author has nothing to disclose.
Medical subject headings
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptides
- Hypoglycemic Agents